Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2007

J&JPRD to Apply Melior’s In Vivo Models

  • Melior Discovery’s theraTRACESM indications discovery platform will be used to identify possible new indications for multiple Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) drug candidates.

    The theraTRACE platform is a multiplexed set of integrated in vivo models that systematically test the potential efficacy of compounds across a large number of disease models. It reduces the time, amount of test compound, and number of test subjects needed while also reducing the number of false positive results, according to the companies.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »